- Home
- GREE vs SABS Comparison
GREE vs SABS Comparison
Compare GREE & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GREE
- SABS
- Stock Information
- Founded
- GREE 1937
- SABS 2014
- Country
- GREE United States
- SABS United States
- Employees
- GREE N/A
- SABS N/A
- Industry
- GREE Investment Bankers/Brokers/Service
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- GREE Finance
- SABS Health Care
- Exchange
- GREE Nasdaq
- SABS Nasdaq
- Market Cap
- GREE 23.4M
- SABS 23.9M
- IPO Year
- GREE N/A
- SABS N/A
- Fundamental
- Price
- GREE $2.00
- SABS $3.34
- Analyst Decision
- GREE Strong Buy
- SABS Strong Buy
- Analyst Count
- GREE 1
- SABS 5
- Target Price
- GREE $4.00
- SABS $12.40
- AVG Volume (30 Days)
- GREE 631.7K
- SABS 83.3K
- Earning Date
- GREE 11-07-2024
- SABS 11-06-2024
- Dividend Yield
- GREE N/A
- SABS N/A
- EPS Growth
- GREE N/A
- SABS N/A
- EPS
- GREE N/A
- SABS N/A
- Revenue
- GREE $64,382,999.00
- SABS $1,512,723.00
- Revenue This Year
- GREE N/A
- SABS N/A
- Revenue Next Year
- GREE N/A
- SABS N/A
- P/E Ratio
- GREE N/A
- SABS N/A
- Revenue Growth
- GREE N/A
- SABS N/A
- 52 Week Low
- GREE $1.62
- SABS $2.16
- 52 Week High
- GREE $9.26
- SABS $7.70
- Technical
- Relative Strength Index (RSI)
- GREE 40.21
- SABS 48.06
- Support Level
- GREE $2.06
- SABS $2.75
- Resistance Level
- GREE $2.24
- SABS $4.30
- Average True Range (ATR)
- GREE 0.17
- SABS 0.51
- MACD
- GREE -0.03
- SABS 0.03
- Stochastic Oscillator
- GREE 6.78
- SABS 26.11
About GREE Greenidge Generation Holdings Inc.
Greenidge Generation Holdings Inc owns and operates a vertically integrated cryptocurrency data center and power generation company. The company owns and operates facilities at two locations: the Town of Torrey, New York, and Spartanburg, South Carolina. The cryptocurrency data center operations generate revenue in the form of bitcoin by earning bitcoin as rewards and transaction fees for supporting the bitcoin network with application-specific integrated circuit computers (ASICs or miners) owned or leased by the company.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.